文献速递眼底病与葡萄膜炎

家庭光学相干断层扫描与持续给药策略:完美结合

Home Optical Coherence Tomography and Sustained Delivery Approaches: A Perfect Marriage.
PubMed 文献 · Am J Ophthalmol · 2024-11-08

本文以循证视角综述新生血管性年龄相关性黄斑变性(nAMD)治疗中持续给药策略与远程监测技术的结合应用。目前,雷珠单抗端口给药系统与家庭光学相干断层扫描(Home OCT)已获美国食品药品监督管理局批准并可供临床使用,文献回顾与病例示例显示二者联合可能降低患者的注射负担与监测负担。其他持续给药策略如酪氨酸激酶抑制剂递送系统和病毒载体介导的抗血管内皮生长因子眼内生物工厂模型尚未获批用于临床。

要点

  • 雷珠单抗端口给药系统与Home OCT已获美国食品药品监督管理局批准并可供临床医生使用。
  • 二者联合的文献回顾与病例示例显示可能降低nAMD患者的注射负担与监测负担。
  • 酪氨酸激酶抑制剂递送系统与病毒载体介导的抗血管内皮生长因子眼内生物工厂模型尚未获批用于临床。

核心结论

  • 持续给药与经验证的远程监测联合使用预示nAMD治疗格局将发生显著变化,并可能在优化患者结局的同时降低患者面临的注射负担与监测负担。

研究设计与样本

  • 循证视角综述,基于文献回顾与作者经验。

主要发现

  • 目前视网膜领域有许多研究致力于安全有效的持续给药和经验证的远程监测。
  • 雷珠单抗端口给药系统和Home OCT已获美国食品药品监督管理局批准并可供临床医生使用。
  • 文献回顾与病例示例显示这些联合技术可能降低nAMD患者当前的注射负担与监测负担。
  • 酪氨酸激酶抑制剂递送系统和病毒载体介导的抗血管内皮生长因子眼内生物工厂模型尚未获批用于临床。
  • 这些技术在临床试验中的早期经验预示了远程监测与多种持续给药方式结合的潜在优势和可能局限性。

临床怎么用

  • 雷珠单抗端口给药系统与Home OCT已获美国食品药品监督管理局批准并可供临床医生使用。
  • 其他持续给药策略如酪氨酸激酶抑制剂递送系统和病毒载体介导的抗血管内皮生长因子眼内生物工厂模型尚未获批用于临床。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To provide a perspective on the management of patients with neovascular age-related macular degeneration (nAMD) using a combination of sustained drug delivery strategies and remote monitoring technology. DESIGN: Evidence-based perspective. METHODS: Review of the literature and experience of the author. RESULTS: There are currently many ongoing research efforts in the retina field directed at both safe, effective sustained drug delivery and validated remote monitoring. At present, the port delivery system with ranibizumab and the Home OCT are approved by the U.S. Food and Drug Administration and available for use by clinicians. A review of available data and a case example demonstrate the potential for these combined technologies to reduce both the injection burden and the monitoring burden currently experienced by patients with nAMD. Other sustained drug delivery strategies such as tyrosine kinase inhibitor delivery systems and viral vector-mediated anti-vascular endothelial growth factor intraocular biofactory models are not yet approved for clinical use. Early experience with these technologies in clinical trials foretell the potential advantages and possible limitations of remote monitoring with a variety of sustained delivery approaches. CONCLUSION: The combined use of sustained drug delivery and validated remote monitoring portends a significant change in the current nAMD treatment landscape and has the potential to reduce the injection and monitoring burden faced by patients while optimizing patient outcomes.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Holekamp NM. Home Optical Coherence Tomography and Sustained Delivery Approaches: A Perfect Marriage. Am J Ophthalmol. 2024. PMID: 39522582. doi:10.1016/j.ajo.2024.10.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。